Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
NCT06393465 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2026-04-29
Summary
This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records
Conditions
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Interventions
- DRUG
-
Tafamidis
61 milligrams under real world conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-06-15
- Primary Completion
- 2026-04-07
- Completion
- 2026-04-07
Countries
- United States
Study Locations
More Related Trials
-
The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy
NCT00694161 ·Status: COMPLETED ·Phase: PHASE2
-
NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
NCT06251778 ·Status: RECRUITING
-
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
NCT07235462 ·Status: RECRUITING
-
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811 ·Status: RECRUITING ·Phase: PHASE3
-
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
NCT06260709 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT03860935 ·Status: COMPLETED ·Phase: PHASE3
-
Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging
NCT03417830 ·Status: TERMINATED ·Phase: PHASE1
-
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
NCT05635045 ·Status: COMPLETED ·Phase: PHASE2
-
SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
NCT05233163 ·Status: COMPLETED ·Phase: PHASE4
-
Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698
NCT03044353 ·Status: TERMINATED ·Phase: PHASE2
-
The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis
NCT05633563 ·Status: COMPLETED ·Phase: PHASE4
-
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy
NCT04360434 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07116473 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Study of AG10 in Amyloid Cardiomyopathy
NCT03458130 ·Status: COMPLETED ·Phase: PHASE2
-
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903 ·Status: RECRUITING ·Phase: PHASE3
-
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
NCT06555237 ·Status: RECRUITING ·Phase: PHASE2
-
A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)
NCT01775761 ·Status: COMPLETED ·Phase: PHASE1
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
NCT05758493 ·Status: RECRUITING ·Phase: PHASE2
-
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
NCT04988386 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
NCT05577819 ·Status: RECRUITING ·Phase: NA
-
A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients
NCT00655538 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
NCT01877915 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.
NCT00353522 ·Status: COMPLETED ·Phase: PHASE2